Drug Profile
Fibrinogen single-component sealant - PPL Therapeutics
Alternative Names: Fibrin 1 sealant - PPL Therapeutics; Fibrin I; Fibrinogen - PPL Therapeutics; Single-component fibrin sealant - PPL TherapeuticsLatest Information Update: 10 Dec 2021
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
- Mechanism of Action Fibrinogen replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Blood coagulation disorders; Wounds
Most Recent Events
- 14 May 2003 PPL Therapeutics will now seek approval for fibrin I as a device
- 19 Feb 2001 This product is available for licensing in USA, Europe and Japan (http://www.ppl-therapeutics.com)
- 19 Feb 2001 Preclinical development for Coagulation disorders in USA (Topical)